https://ir.opgen.com/news/opgen-receives-expected-nasdaq-notice-regarding-delayed-form-10-q/2024-05-24T20:05:00+00:00https://ir.opgen.com/news/opgen-announced-1-for-10-reverse-stock-split/2024-05-16T11:00:00+00:00https://ir.opgen.com/news/opgen-provides-update-on-business-operations-and-strategic-opportunities/2024-04-29T20:05:00+00:00https://ir.opgen.com/news/opgen-receives-nasdaq-notice-regarding-delayed-form-10-k/2024-04-23T20:15:00+00:00https://ir.opgen.com/news/opgen-announces-acquisition-of-preferred-stock-by-david-lazar/2024-03-25T20:05:00+00:00https://ir.opgen.com/news/opgen-reports-third-quarter-2023-financial-results-and-provides-business-update/2023-11-14T21:30:00+00:00https://ir.opgen.com/news/opgen-enters-into-warrant-inducement-transaction-for-up-to-11-2-million-in-gross-proceeds/2023-10-12T16:32:00+00:00https://ir.opgen.com/news/opgen-reports-second-quarter-2023-financial-results-and-provides-business-update/2023-08-10T20:15:00+00:00https://ir.opgen.com/news/opgens-subsidiary-ares-genetics-releases-new-features-to-its-arescloud-offering/2023-08-07T11:30:00+00:00https://ir.opgen.com/news/opgens-subsidiary-curetis-and-find-extend-rd-collaboration-agreement/2023-08-03T12:00:00+00:00https://ir.opgen.com/news/opgen-to-provide-business-update-and-financial-results-for-the-second-quarter-2023-on-august-10th-at-430-p-m-eastern-time/2023-08-03T11:30:00+00:00https://ir.opgen.com/news/opgens-subsidiary-curetis-meets-milestones-of-extended-and-expanded-rd-collaboration-with-find/2023-07-19T11:30:00+00:00https://ir.opgen.com/news/opgen-subsidiary-ares-genetics-successfully-maintains-key-patent-under-opposition-in-europe/2023-06-26T11:30:00+00:00https://ir.opgen.com/news/opgens-subsidiary-curetis-receives-batch-of-ten-new-c-series-unyvero-a30-instruments/2023-06-22T11:30:00+00:00https://ir.opgen.com/news/opgen-presents-unyvero-urinary-tract-infection-panel-trial-results-at-asm-microbe-2023-conference/2023-06-20T11:30:00+00:00https://ir.opgen.com/news/opgen-reports-first-quarter-2023-financial-results-and-provides-business-update/2023-05-15T20:15:00+00:00https://ir.opgen.com/news/opgen-to-provide-business-update-and-financial-results-for-the-first-quarter-2023-on-may-15th-at-430-p-m-eastern-time/2023-05-08T11:30:00+00:00https://ir.opgen.com/news/opgen-announces-closing-of-3-5-million-public-offering/2023-05-04T20:30:00+00:00https://ir.opgen.com/news/opgen-announces-pricing-of-3-5-million-public-offering/2023-05-02T01:00:00+00:00https://ir.opgen.com/news/opgens-subsidiary-curetis-meets-all-remaining-key-milestones-in-rd-collaboration-with-find/2023-04-26T20:30:00+00:00